| Non-Small Cell Lung Carcinoma
Retevmo vs Tagrisso
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Retevmo vs Tagrisso with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTagrisso has a higher rate of injection site reactions vs Retevmo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tagrisso but not Retevmo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Retevmo
Tagrisso
At A Glance
Oral
Twice daily
RET kinase inhibitor
Oral
Daily
EGFR kinase inhibitor
Indications
- Non-Small Cell Lung Carcinoma
- Medullary carcinoma of thyroid
- Thyroid carcinoma
- Non-Small Cell Lung Carcinoma
Dosing
Non-Small Cell Lung Carcinoma, Medullary carcinoma of thyroid, Thyroid carcinoma Adults and adolescents >= 12 years: 120 mg orally twice daily (< 50 kg) or 160 mg orally twice daily (>= 50 kg); pediatric patients 2 to < 12 years: 40 mg three times daily to 160 mg twice daily orally based on body surface area; administered until disease progression or unacceptable toxicity.
Adjuvant Non-Small Cell Lung Carcinoma 80 mg orally once daily until disease recurrence, unacceptable toxicity, or for up to 3 years.
Locally advanced, unresectable (Stage III) Non-Small Cell Lung Carcinoma Following platinum-based chemoradiation therapy, 80 mg orally once daily until disease progression or unacceptable toxicity.
First-line metastatic Non-Small Cell Lung Carcinoma (monotherapy) 80 mg orally once daily until disease progression or unacceptable toxicity.
First-line locally advanced or metastatic Non-Small Cell Lung Carcinoma (combination) 80 mg orally once daily in combination with pemetrexed and platinum-based chemotherapy until disease progression or unacceptable toxicity.
Previously treated EGFR T790M mutation-positive metastatic Non-Small Cell Lung Carcinoma 80 mg orally once daily until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=25%) edema, diarrhea, fatigue, dry mouth, hypertension, abdominal pain, constipation, rash, nausea, headache
Serious hepatotoxicity, interstitial lung disease/pneumonitis, hypertension, QT interval prolongation, hemorrhagic events, hypersensitivity, tumor lysis syndrome, impaired wound healing, hypothyroidism, slipped capital femoral epiphysis in adolescents
Postmarketing Stevens-Johnson Syndrome
Most common (>=20%) Diarrhea, rash, musculoskeletal pain, nail toxicity, dry skin, stomatitis, fatigue.
Serious ILD/pneumonitis, QTc interval prolongation, cardiomyopathy, keratitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, cutaneous vasculitis, aplastic anemia.
Postmarketing Erythema multiforme major, Stevens-Johnson syndrome, toxic epidermal necrolysis, cutaneous vasculitis, erythema dyschromicum perstans, aplastic anemia.
Pharmacology
Selpercatinib is a kinase inhibitor that selectively inhibits wild-type RET and multiple mutated RET isoforms (including gene fusions and activating point mutations) as well as VEGFR1 and VEGFR3, and at clinically achievable concentrations also inhibits FGFR1, 2, and 3, blocking constitutive RET signaling that acts as an oncogenic driver promoting tumor cell proliferation.
Osimertinib is a kinase inhibitor that irreversibly binds to mutant EGFR forms (T790M, L858R, and exon 19 deletions) at approximately 9-fold lower concentrations than wild-type EGFR, inhibiting tumor cell proliferation in EGFR mutation-positive NSCLC; it also inhibits HER2, HER3, HER4, ACK1, and BLK at clinically relevant concentrations.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
No coverage data available for Retevmo.
Tagrisso
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Retevmo
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Tagrisso
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (5/8)
Humana
Retevmo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Tagrisso
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Retevmo.
Cost estimate not availableAssistance Fund: Non-Small Cell Lung Cancer (NSCLC)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RetevmoView full Retevmo profile
TagrissoView full Tagrisso profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.